ARTL Director Connie Matsui Receives 136-Share Award

What Happened
Connie Matsui, a director of Artelo Biosciences, was granted an award covering 136 derivative shares on July 17, 2026. The filing reports an acquisition price of $0.00 (total reported value $0). This is a compensatory grant/award rather than an open-market purchase or sale.

Key Details

• Transaction date: July 17, 2026. Filing date (accession): July 21, 2026.
• Transaction type/code: A — Grant/award or other acquisition (derivative).
• Shares/units granted: 136; reported acquisition price: $0.00 (total $0 as reported).
• Shares owned after transaction: Not specified in the provided excerpt.
• Vesting: Per footnote — 100% of the shares subject to the option vest on the earlier of (i) one year after the Vesting Commencement Date or (ii) the day before the issuer’s next annual meeting. Vesting Commencement Date = July 17, 2026. Vesting is conditioned on continued service.
• Filing timeliness: Filing dated July 21 for a July 17 transaction; the provided excerpt does not mark this as late.

Context
This appears to be a time‑based equity award (the footnote references an option-style vesting schedule). Such awards are standard director compensation and do not represent an immediate purchase or sale of stock. They vest only if the director remains a service provider through the vesting date, so they are contingent and may dilute shares if and when vested/issued.